The effect of statins on mortality in septic patients: A meta-analysis of randomized controlled trials

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Pasin, Laura ^a   Landoni, Giovanni ^a,b   Castro, Maria Lourdes ^c   Cabrini, Luca ^a   Belletti, Alessandro ^a   Feltracco, Paolo ^d   Finco, Gabriele ^e   Carozzo, Andrea ^a   Chiesa, Roberto ^a   Zangrillo, Alberto ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b Maieutics Foundation   (Italy)

^c Centro Hospitalar de Lisboa Central Maternidade   (Portugal)

^d UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^e UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD COAGULATION; CYTOKINES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION MEDIATORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEPSIS;

EID: 84894248128     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082775     Document Type: Article

References (38)

1. Endo A (1992) The discovery and development of HMG-CoA inhibitors. J Lipid Res 33: 1569-1582.
2. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, et al. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: results of the Cholesterol and Recurrent Events (CARE) trial. N Engl J Med 335: 1001-1009. (Pubitemid 26338729)
3. Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389.
4. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, et al. (2005) C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352: 20-28. (Pubitemid 40075677)
5. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto Jr AM, et al. (2009) Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373: 1175-1182.
6. Kopterides P, Falagas ME (2009) Statins for sepsis: a critical and updated review. Clin Microbiol Infect 15: 325-334.
7. Kuoppala J, Lamminpaa A, Pukkala E (2008) Statins and cancer: A systematic review and meta-analysis. Eur J Cancer 44: 2122-2132.
8. Blum A, Shamburek R (2009) The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis 203: 325-330.
9. Jain MK, Ridker PM (2005) Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 4: 977-987.
10. Kwak B, Mulhaupt F, Myit S, Mach F (2000) Statins as a newly recognized type of immunomodulator. Nat Med 6(12): 1399-1402. (Pubitemid 32001026)
11. Steiner S, Speidl WS, Pleiner J, Seidinger D, Zorn G, et al. (2005) Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation 111(14): 1841-1846. (Pubitemid 40525151)
12. Shi J, Wang J, Zheng H, Ling W, Joseph J, et al. (2003) Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation. Blood Coagul Fibrinolysis 14(6): 575-585. (Pubitemid 37083174)
13. Youssef S, Stüve O, Patarroyo JC, Ruiz PJ, Radosevich JL, et al. (2002) The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420:78-84. (Pubitemid 35291443)
14. Zeiser R, Youssef S, Baker J, Kambham N, Steinman L, et al. (2007) Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. Blood 110: 4588-4598. (Pubitemid 351377828)
15. Wang Y, Chang H, Zou J, Jin X, Qi Z (2011) The effect of atorvastatin on mRNA levels of inflammatory genes expression in human peripheral blood lymphocytes by DNA microarray. Biomed Pharmacother 65: 118-122.
16. Kruger PS, Harward ML, Jones MA, Joyce CJ, Kostner KM, et al. (2011) Continuation of statin therapy in patients with presumed infection: a randomized controlled trial. Am J Respir Crit Care Med 183(6): 774-81.
17. Kruger P, Bailey M, Bellomo R, Cooper DJ, Harward M, et al. (2013) The ANZ- STATInS Investigators - ANZICS Clinical Trials Group. A Multicentre Randomised Trial of Atorvastatin Therapy in Intensive Care Patients with Severe Sepsis. Am J Respir Crit Care Med 187(7): 743-50.
18. Patel JM, Snaith C, Thickett DR, Linhartova L, Melody T, et al. (2012) Randomized double-blind placebo-controlled trial of 40 mg/day of atorvastatin in reducing the severity of sepsis in ward patients (ASEPSIS Trial). Crit Care 16(6): R231.
19. Higgins JPT, Green S (2011) Cochrane handbook for systematic reviews of interventions. Version 5.1.0. Available: http://www.cochranehandbook.org. Accessed: July 2012.
20. Biondi-Zoccai G, Lotrionte M, Landoni G, Modena MG (2011) The rough guide to systematic reviews and meta-analyses. HSR Proc Intensive Care Cardiovasc Anesth 3: 161-173.
21. Biondi-Zoccai G, Landoni G, Modena MG (2011) A journey into clinical evidence: from case report to mixed treatment comparisons. HSR Proc Intensive Care Cardiovasc Anesth 3(2): 93-96.
22. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339: b2700. doi: 10.1136/bmj.b2700.
23. Trezzi M, Blackstone EH, Sun Z, Li L, Sabik 3rd JF, et al. (2013) Statin therapy is associated with fewer infections after cardiac operations. Ann Thorac Surg 95(3): 892-900.
24. Ferrari GL, Quinto BM, Queiroz KC, Iizuka IJ, Monte JC, et al. (2011) Effects of simvastatin on cytokines secretion from mononuclear cells from critically ill patients with acute kidney injury. Cytokine 54(2): 144-8. doi: 10.1016/j.cyto2011.02.005. Epub 2011 Mar 1.
25. Donnino MW, Cocchi MN, Howell M, Clardy P, Talmor D, et al. (2009) Statin therapy is associated with decreased mortality in patients with infection. Acad Emerg Med 16(3): 230-4.
26. Tseng MY, Hutchinson PJ, Czosnyka M, Richards H, Pickard JD, et al. (2007) Effects of acute pravastatin treatment on intensity of rescue therapy, length of inpatient stay, and 6-month outcome in patients after aneurysmal subarachnoid hemorrhage. Stroke 38(5): 1545-50. (Pubitemid 46684172)
27. Makris D, Manoulakas E, Komnos A, Papakrivou E, Tzovaras N, et al. (2011) Effect of pravastatin on the frequency of ventilator-associated pneumonia and on intensive care unit mortality: open-label, randomized study. Crit Care Med 39(11): 2440-6.
28. Craig TR, Duffy MJ, Shyamsundar M, McDowell C, O'Kane CM, et al. (2011) A randomized clinical trial of hydroxymethylglutaryl- coenzyme a reductase inhibition for acute lung injury (The HARP Study). Am J Respir Crit Care Med 183(5): 620-6.
29. Robinson K, Kruger P, Phillips LK, Prins J, Venkatesh B (2011) Effect of statin therapy on plasma adiponectin concentrations in patients with the sepsis syndrome: a preliminary investigation. Intensive Care Med 37(8): 1388-9.
30. Novack V, Eisinger M, Frenkel A, Terblanche M, Adhikari NK, et al. (2009) The effects of statin therapy on inflammatory cytokines in patients with bacterial infections: a randomized double-blind placebo controlled clinical trial. Intensive Care Med 35(7): 1255-60.
31. Choi HS, Park MJ, Kang HM, Kim YJ, Choi CW, et al. (2008) Statin use in sepsis due to pneumonia. Poster #920. Presented May 16-18, 2008 International Conference, Toronto, Canada.
32. Ando H, Takamura T, Ota T, Nagai Y, Kobayashi K (2000) Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J Pharmacol Exp Ther 294: 1043-6. (Pubitemid 30666857)
33. Merx MW, Liehn EA, Graf J, van de Sandt A, Schaltenbrand M, et al. (2005) Statin treatment after onset of sepsis in a murine model improves survival. Circulation 112: 117-124. (Pubitemid 40962577)
34. Janda S, Young A, Fitzgerald JM, Etminan M, Swiston J (2010) The effect of statins on mortality from severe infections and sepsis: a systematic review and meta-analysis. J Crit Care 25(4): 656.e7-22.
35. Chopra V, Rogers MA, Buist M, Govindan S, Lindenauer PK, et al. (2012) Is statin use associated with reduced mortality after pneumonia? A systematic review and meta-analysis. Am J Med 125(11): 1111-23.
36. Stagnitti MN (2008) Trends in statins utilization and expenditures for the U.S. civilian noninstitutionalized population, 2000 and 2005. In Medical Expenditure Panel Survey: Statistical Brief #205. Edited by Agency for Healthcare Research and Quality. Rockville: Agency for Healthcare Research and Quality.
37. Hotchkiss RS, Karl IE (2003) The pathophysiology and treatment of sepsis. N Engl J Med 348: 138-150. (Pubitemid 36056721)
38. Armitage J (2007) The safety of statins in clinical practice. Lancet 370: 1781-1790.